Business Wire Feed

Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma

April 8th, 2026|

First-in-class TET2 activator targets DNA damage response in GBM and other cancers Strong preclinical efficacy, brain penetration, and safety profile support clinical advancement Study led by world-leading glioblastoma investigators, including Dr. Roger StuppOSLO, Norway--(BUSINESS WIRE)--#Biotech--Hemispherian more...

Bruker Invests in Photothermal AFM-IR to Advance Semiconductor Research

April 7th, 2026|

Dimension IconIR to Support Critical Materials Characterization for Next-Generation Semiconductor Devices BILLERICA, Mass.--(BUSINESS WIRE)--$BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced accelerated development of its photothermal AFM-IR spectroscopy capabilities to address research challenges facing the semiconductor more...

Alzheon Advances Industry-Leading Portfolio of Oral Anti-Amyloid Aggregation Inhibitors with First Subject Dosed in Phase 1 of ALZ-507, Highlighting Potential for Once-Daily Administration, Improved Safety and Efficacy, and APOE4 Corrector Mechanism

April 7th, 2026|

ALZ-507 Designed as Well-Differentiated Oral Candidate Targeting Soluble Amyloid Oligomer Pathology, with Additional Mechanism of Action as APOE4 Corrector ALZ-507 IND Program Demonstrated Favorable Nonclinical Safety and Pharmacokinetic Profile that Supports Once-Daily Dosing ALZ-507 Broadens more...

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.